Chi-Med announced that solepinib has been granted orphan drug status by the US Food and Drug Administration to treat primary immune thrombocytopenia. Immune thrombocytopenia is an autoimmune disorder that causes an increased risk of bleeding. Solepinib is a novel, highly selective oral spleen tyrosine kinase inhibitor.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.